Topic: drug reimbursement
As JPM kicks into gear, Novartis CEO Vas Narasimhan and British health officials unveiled a new access agreement on inclisiran.
Patients with small cell lung cancer don’t have a lot of options. But that fact didn’t convince NICE to foot the bill for Roche's Tecentriq.
Astellas buys gene therapy player Audentes for $3 billion. Keytruda and Opdivo fail to win coverage in China. Hanmi inks I-O deal with Rapt.
It’s a familiar scene in the race onto China’s national reimbursement list: Drugmakers cut prices by an average 60.7% to win coverage.
Rival PARP inhibitors by GSK and AstraZeneca-Merck already have their own NICE backing, though neither of the three is on routine coverage.
Vertex hasn't been able to reach a deal for cystic fibrosis drug access in England, but in neighbor Scotland, the company has struck a five-year agreement.
New CMS rules have removed some restrictions on healthcare providers that could in turn boost uptake of Gilead's and Novartis' CAR-T drugs.
Contradicting analysts' observations, Novartis CEO dubbed Zolgensma “one of the most successful launches from an access standpoint in rare diseases.”
England’s cost watchdogs won’t get behind AZ blockbuster Tagrisso. But in a change of events, they’re instead backing a Pfizer challenger.
Sanofi and Regeneron’s Libtayo is two for two in the last two days—at winning over key European regulatory and reimbursement bodies, that is.